Logo image of ACON

ACLARION INC (ACON) Stock Overview

USA - NASDAQ:ACON - US6551874091 - Common Stock

7.71 USD
+0.06 (+0.78%)
Last: 10/28/2025, 8:00:00 PM
8 USD
+0.29 (+3.76%)
After Hours: 10/28/2025, 8:00:00 PM

ACON Key Statistics, Chart & Performance

Key Statistics
Market Cap5.01M
Revenue(TTM)62.90K
Net Income(TTM)-7060300
Shares650.00K
Float650.00K
52 Week High3499.51
52 Week Low6.2
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2155.52
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2022-04-22
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Technology
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Technology


ACON short term performance overview.The bars show the price performance of ACON in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

ACON long term performance overview.The bars show the price performance of ACON in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ACON is 7.71 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -99.54%.

ACLARION INC / ACON Daily stock chart

ACON Latest News, Press Relases and Analysis

ACON Competitors/Peers

The largest stocks on the US markets in the "Health Care Technology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
VEEV VEEVA SYSTEMS INC-CLASS A 39.11 47.76B
DOCS DOXIMITY INC-CLASS A 44.62 12.45B
WAY WAYSTAR HOLDING CORP 35.58 7.54B
HTFL HEARTFLOW INC N/A 3.19B
CERT CERTARA INC 24.76 1.95B
SDGR SCHRODINGER INC N/A 1.60B
TDOC TELADOC HEALTH INC N/A 1.48B
PHR PHREESIA INC N/A 1.40B
GDRX GOODRX HOLDINGS INC-CLASS A 10.46 1.27B
CTEV CLARITEV CORP N/A 1.17B
LFMDP LIFEMD INC - LFMD 8 7/8 PERP N/A 1.07B
CCLDO CARECLOUD INC - CCLD 8 3/4 PERP N/A 899.72M

About ACON

Company Profile

ACON logo image Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Company Info

ACLARION INC

8181 Arista Place, Ste 100

Broomfield COLORADO US

Employees: 6

ACON Company Website

ACON Investor Relations

Phone: 18332752266

ACLARION INC / ACON FAQ

What does ACLARION INC do?

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.


What is the current price of ACON stock?

The current stock price of ACON is 7.71 USD. The price increased by 0.78% in the last trading session.


Does ACLARION INC pay dividends?

ACON does not pay a dividend.


What is the ChartMill rating of ACLARION INC stock?

ACON has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Should I buy ACON stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACON.


Can you provide the ownership details for ACON stock?

You can find the ownership structure of ACLARION INC (ACON) on the Ownership tab.


Can you provide the short interest for ACON stock?

The outstanding short interest for ACLARION INC (ACON) is 12.32% of its float.


ACON Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ACON. When comparing the yearly performance of all stocks, ACON is a bad performer in the overall market: 96.49% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ACON Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ACON. No worries on liquidiy or solvency for ACON as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ACON Financial Highlights

Over the last trailing twelve months ACON reported a non-GAAP Earnings per Share(EPS) of -2155.52. The EPS increased by 93.02% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -47.85%
ROE -49.76%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%99.8%
Sales Q2Q%76.12%
EPS 1Y (TTM)93.02%
Revenue 1Y (TTM)16.48%

ACON Forecast & Estimates

7 analysts have analysed ACON and the average price target is 20.4 USD. This implies a price increase of 164.59% is expected in the next year compared to the current price of 7.71.

For the next year, analysts expect an EPS growth of 99.81% and a revenue growth 100% for ACON


Analysts
Analysts82.86
Price Target20.4 (164.59%)
EPS Next Y99.81%
Revenue Next Year100%

ACON Ownership

Ownership
Inst Owners0.77%
Ins Owners0%
Short Float %12.32%
Short Ratio0.47